Navigation Links
Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
Date:2/17/2009 

    DUSSELDORF, Germany, February 17 /PRNewswire/ --

    - Sales Grow by 10.7% to EUR1.06bn

    - Adjusted Earnings per Share Improves by 36.6% From EUR1.34 Euro to
      EUR1.83

    - Adjusted EBITDA Margin Rises From 19.0 to 19.5%

    - CEO Dr. Axel Herberg: "Following the record year in 2008 Gerresheimer
      again considers itself well equipped to meet the global challenges in
      2009 and is aiming for further substantial sales growth of 6% to 7% in
      the core business."

In 2008 Gerresheimer AG had another record year marked by important milestones, and achieved all its published objectives. The international Group with its main base in Dusseldorf, Germany, increased its sales by 10.7% (12.8% on a like-for-like exchange-rate basis) and thereby passed the billion euro mark. Operating results (Adjusted EBITDA) rose by 13.7% to EUR206.4m (prior year: EUR181.6m). The Adjusted EBITDA margin reached 19.5% in 2008 (prior year: 19%). There was a substantial improvement of 36.6% in adjusted earnings per share in the past financial year to EUR1.83 (prior year EUR1.34).

"Our strategy of internationalization and focus is bearing fruit," says Dr. Axel Herberg, CEO of Gerres-heimer AG. "Even in a phase of worldwide economic downturn, pharmaceutics and life science are still growth markets and, with its broad technology base and worldwide presence, Gerresheimer has a strong position here." The shareholders of Gerresheimer AG should participate in the success of Gerresheimer AG as in the prior year. The Management Board and Supervisory Board of Gerresheimer AG will therefore propose to the Shareholders' Meeting that a dividend of EUR0.40 per share is paid.

In December 2008, Gerresheimer AG was included in the second-largest German selection index MDax. This means increased visibility for our company on capital markets, and greater appeal for our shares.

Further substa
'/>"/>

SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
11. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... N.Y. , June 18, 2013  AMRI ... its Burlington, Mass. , site ... Drug Enforcement Administration (DEA) registration to handle Schedule ... the DEA,s acknowledgement of Burlington,s ... control and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ...
(Date:6/18/2013)... 2013 This webinar will examine ... and promotion, and review the basic FDA regulations ... to apply these principles through real world case ...     The fundamentals on FDA regulations and guidance related ...     Assessing traditional and newer forms of promotional ...
(Date:6/18/2013)... June 18, 2013 As a ... Inc proudly announces the release of their infographic ... Fitness ". , MeMD's goal was to leverage ... of Health 2.0, Health 3.0 and mHealth.The infographic ... transform medical care and the fitness industry in ...
(Date:6/18/2013)... Minneapolis, MN (PRWEB) June 18, 2013 ... the Saniclave 200 prevent the dangers of ... confusing features, like knobs, analog pressure gauges, hot surfaces ... older autoclave, or a new, modern autoclave, Revolutionary Science ... use fresh water. Older autoclave designs will recycle ...
Breaking Biology Technology:AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2How to Autoclave: Why the User Friendliness of the Saniclave 200 is So Important Today 2
... Neogen Corporation (NASDAQ: NEOG ) announced today ... seafood testing laboratory from its parent company, GlycoMar Ltd. ... services to the shellfish and salmon aquaculture industries. VeroMara,s ... including E. coli , noroviruses, and salmon husbandry. ...
... 2011 , Kuros Biosurgery AG, ... biomaterials and bioactive-biomaterial,combination products for trauma, wound and ... Application,00910049 by the European Patent Office. This now ... broad portfolio of applications,and patents designed to protect ...
... TRIANGLE PARK, N.C., June 17, 2011 Max ... the prestigious Max Group whose sister-company, Max Healthcare ... of Minimal Access, Metabolic & Bariatric Surgery, accredited ... Surgical Review Corporation (SRC), USA.  The institute has ...
Cached Biology Technology:Neogen Acquires VeroMara from GlycoMar Ltd. 2Kuros Announces Allowance of European Patent for Synthetic Biomaterials 2Kuros Announces Allowance of European Patent for Synthetic Biomaterials 3Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery 2
(Date:6/18/2013)... New research from the University of Adelaide shows that ... a baby,s life is linked to a higher IQ at early ... Public Health researchers, who analysed data from more than 13,800 children ... Pediatrics , show that babies who put on ... IQ 1.5 points higher by the time they were six years ...
(Date:6/17/2013)... Researchers have identified a new virus in patients with ... to determine whether the virus is responsible for the ... a total of 28 out of 644 patients with ... 4%, but not in any of the 122 patients ... of the brain and central nervous system are often ...
(Date:6/17/2013)... June 6, professors in Wayne State University,s Department ... Foundation-funded (NSF) Research Experience for Undergraduates (REU) program. ... to do cutting-edge research in astrophysics, and in ... Alexey Petrov, Ph.D., professor of physics in Wayne ... and program director of the grant, the student ...
Breaking Biology News(10 mins):IQ link to baby's weight gain in first month 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3Wayne State welcomes undergraduates from around the US for physics research experience 2
... certain enzyme can resist the normal effects of a heart ... and still-oxygenated heart tissue, according to a study by researchers ... the possibility of a therapy that could stimulate the growth ... as well as prevent an attack from occurring at all, ...
... Researchers at the Department of Energy,s Oak Ridge National ... at how developing nerve cells may hold a key ... and Parkinson,s disease. St. Jude scientists have linked ... the brains and retinas of young mice to certain ...
... damage can be triggered by various insults, including hepatitis ... can lead to cancer. A new study by researchers ... reveals how one protein helps decide the fate of ... online on March 30th in the Journal of ...
Cached Biology News:A missing enzyme conveys major heart protection in pre-clinical work 2A missing enzyme conveys major heart protection in pre-clinical work 3ORNL, St. Jude track neurons to predict and prevent disease 2
... peptide derived from the C-terminal region of ... D iris-expressed growth factor spinal cord-derived growth ... rat by one amino acid replacement. ... mouse and rat PDGF-D proteins. Reactivity: ...
Antibodies were affinity purified using epitopes specific to USP33 immobilized on solid support....
...
... 100% ,human IgG subclass 2 ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... IgG Fab ...
Biology Products: